SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Job Trends
The BioMidwest Region Features Lifestyle Bonuses and Cutting-Edge Science
Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?
July 26, 2021
 · 
4 min read
 · 
Heather McKenzie
Founder and CEO, Agustin Fernand of Rational Vacci
Policy
A Rationally Designed Therapeutic Vaccine for Herpes
A vaccine for herpes is under development and Rational Vaccines are going to make this a reality very soon. Here’s everything you need to learn about it.
July 25, 2021
 · 
5 min read
 · 
Heather McKenzie
Business
Lisa Stockman Mauriello Receives First Tofersen Treatment - UPDATED
Phase one launched last week after patients who had been on placebo in Biogen’s pivotal phase III VALOR study were transitioned to active therapy.
July 23, 2021
 · 
3 min read
 · 
Heather McKenzie
Nicole Brackett, a postdoctoral scientist at Indo
Drug Development
Fel d 1 Protein Sparking Curiosity that Could Change the Cat
Companies such as Indoor Biotechnologies in Virginia are leveraging cutting-edge scientific techniques to knock out the Fel d 1 protein completely from the cats.
July 22, 2021
 · 
5 min read
 · 
Heather McKenzie
Pharm Country
BioSpace’s Business Report Highlights Sustained Growth and New Blood
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
July 22, 2021
 · 
5 min read
 · 
Heather McKenzie
Koselugo is the new evolution in the Rare Plexifor
Policy
Koselugo: The First Non-Surgical Alternative for Rare Plexiform Neurofibroma
Notably, Koselugo was studied in pediatric populations first, a reversal of the typical development path taken by the majority of drugs.
July 21, 2021
 · 
5 min read
 · 
Heather McKenzie
Rivus Chief Executive Officer, Allen Cunningham/Ph
Business
Rivus Pharmaceuticals Striving for Fundamental Change in Cardio-metabolic Disorders
Rivus’ CMAs are designed to overcome these illnesses by activating the body’s natural process of mitochondrial uncoupling.
July 19, 2021
 · 
3 min read
 · 
Heather McKenzie
Drug Development
AB Science Announces Significant Survival Data for Masitinib in ALS
The recent survival results of Masitinib will help (ALS) patients to live longer. AB Science has successfully established the sweet spot for masitinib in ALS.
July 19, 2021
 · 
3 min read
 · 
Heather McKenzie
Biotech Bay
Bay Area Biotech Companies Hiring Now
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
July 15, 2021
 · 
6 min read
 · 
Heather McKenzie
Pharm Country
Navigating Biotech Risks from Discovery to Approval
Up and down the development pipeline, there are vulnerabilities. From shareholder expectations and IP protection to clinical trial risk and cyberattacks, it’s a minefield and enlisting a risk management partner is vital.
July 12, 2021
 · 
8 min read
 · 
Heather McKenzie
Business
Evidence Building for a Mix and Match Approach to COVID-19 Vaccines
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
July 12, 2021
 · 
5 min read
 · 
Heather McKenzie
Sana employees, pictured in a company laboratory,
Business
Inclusion and Diversity is Paramount to Sana’s Patient-Centric Culture
Sana Biotechnology, a gene and cell therapy hybrid whose mission is to create and deliver engineered cells as medicines for patients, puts the “I” first in Inclusion, Diversity and Equity (IDE).
July 9, 2021
 · 
5 min read
 · 
Heather McKenzie
Business
Promised EAP Date Approaching for Biogen’s Highly Publicized ALS Drug
Tofersen is the furthest along of four ASOs currently in clinical development for ALS and as such, there is quite a bit riding on the results of the VALOR trial which has an estimated completion date of August 31st, 2021.
June 28, 2021
 · 
6 min read
 · 
Heather McKenzie
Intellia President and CEO John Leonard, M.D./Phot
Drug Development
UPDATED: In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside the Body
Interim results from the Phase I study presented at the Peripheral Nerve Society Annual Meeting demonstrated that the investigational therapy, NTLA-2001, greatly reduced the disease-causing protein after a single infusion.
June 27, 2021
 · 
4 min read
 · 
Heather McKenzie
Rafael Henrique/SOPA Images/LightRocket
Drug Development
Will Intellia Make Gene Editing History Saturday?
In what will be a big moment for CRISPR technology, Intellia and development partner, Regeneron Pharmaceuticals will share the world’s first data from a therapy that edits flawed genes inside the body.
June 25, 2021
 · 
2 min read
 · 
Heather McKenzie
Load More